Johnson & Johnson’s JNJ subsidiary, Janssen Biotech, Inc. announced that it has submitted two Supplemental Biologics License Applications (sBLAs) in the U.S., seeking approval of Simponi Aria for the ...
As the controversial Alzheimer's disease (AD) drug aducanumab (Aduhelm) begins its integration into clinical practice, some physicians are concerned the drug's prescribing label does not include ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results